Pmv Pharmaceuticals, Inc. (PMVP) Stock Price & Analysis
Pmv Pharmaceuticals, Inc. (PMVP) fell 6.77% to USD 1.24 as of July 25, 2026 at 03:40 UTC, according to Nexqual real-time market data.
PMVP last closed at USD 1.33; the session ranged USD 1.23–1.35 on volume of 131,928 shares. Market capitalization is $66.13M, with a 52-week range of USD 1.02–1.88 (NMS). Source: Nexqual, July 25, 2026 at 03:40 UTC.
Key Statistics (as of July 25, 2026 at 03:40 UTC)
| Price | USD 1.24 |
|---|---|
| Change | ▼ 6.77% (down) |
| Previous Close | USD 1.33 |
| Open | USD 1.34 |
| Day Range | USD 1.23 – 1.35 |
| 52-Week Range | USD 1.02 – 1.88 |
| Volume | 131,928 shares |
| Market Cap | $66.13M |
| Exchange | NMS |
Technical Analysis (PMVP)
Nexqual's technical model rates PMVP "NEUTRAL" based on 3 bullish and 3 bearish signals across 125 daily candles, as of July 25, 2026 at 03:40 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.67 (neutral) |
| vs SMA50 | Above (USD 1.22) |
| MACD | 0.03 (positive) |
Analyst Ratings (PMVP)
Wall Street analysts rate PMVP "None" based on 4 analysts, with a mean price target of USD 4 (range USD 3–5), per Nexqual as of July 25, 2026 at 03:40 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 4 |
| High Target | USD 5 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (PMVP)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.4 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.34 vs est -0.39 ▲ beat |
| 2025-12-31 | USD -0.34 vs est -0.4 ▲ beat |
| 2025-09-30 | USD -0.4 vs est -0.4 ▲ beat |
| 2025-06-30 | USD -0.41 vs est -0.39 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:40 UTC.
Financials & Fundamentals (PMVP)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -63.16% |
| Debt / Equity | 0.33 |
| Current Ratio | 11.14 |
| Total Cash | $93.55M |
| Total Debt | $293,000 |
| Free Cash Flow | $-46.59M |
Source: Nexqual, July 25, 2026 at 03:40 UTC.
Financial Health Score (PMVP)
Nexqual rates Pmv Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:40 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $94M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$75M |
| Efficiency | Critical — ROE -63%, ROA -39.1% |
Ownership (PMVP)
| Insider Ownership | +3.35% |
|---|---|
| Institutional Ownership | +67.74% |
| Shares Outstanding | 53.33M |
| Float | 43.14M |
| Short % of Float | +5.65% |
Source: Nexqual, July 25, 2026 at 03:40 UTC.
Leadership (PMVP)
Pmv Pharmaceuticals, Inc. is led by David H. Mack (age 63), Co-Founder, CEO, President & Director, per Nexqual as of July 25, 2026 at 03:40 UTC.
| Co-Founder, CEO, President & Director | David H. Mack (age 63) |
|---|---|
| Co-Founder, Independent Director & Member of Scientific Advisory Board | Arnold J. Levine (age 85) |
| General Counsel, COO & Company Secretary | Robert Ticktin (age 63) |
| Chief Financial Officer | Michael Carulli (age 51) |
| Vice President of Human Resources | Crystal Zuckerman |
Major Backers & Investors (PMVP)
Notable institutional backers of Pmv Pharmaceuticals, Inc. include BML Capital Management, LLC, Tang Capital Management, LLC, Sio Capital Management, LLC, according to Nexqual as of July 25, 2026 at 03:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| BML Capital Management, LLC | 9.98% |
| Tang Capital Management, LLC | 7.96% |
| Sio Capital Management, LLC | 5.77% |
| ArrowMark Colorado Holdings LLC | 5.39% |
| Euclidean Capital Llc | 4.93% |
| Eversept Partners, LP | 4.4% |
| Acadian Asset Management. LLC | 4.15% |
| Two Sigma Investments, LP | 3.53% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.34% |
Source: Nexqual, July 25, 2026 at 03:40 UTC.
From Pmv Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-06)
Key Strengths & Strategy (as disclosed to the SEC)
- PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States.
- It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PRLD | Prelude Therapeutics Incorporat | USD 3.83 | ▼ 2.42% |
| ALXO | ALX Oncology Holdings Inc. | USD 2.03 | ▲ 0.5% |
| NKTX | Nkarta, Inc. | USD 2.27 | ▼ 5.81% |
| CCCC | C4 Therapeutics, Inc. | USD 3.4 | ▼ 9.09% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | USD 4.33 | ▼ 3.78% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:40 UTC. This page is informational and not investment advice.